Navigation Links
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Date:2/27/2008

MOUNTAIN VIEW, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Michael J. Simms has joined the company as Senior Vice President, Operations and Manufacturing. Mr. Simms was most recently Senior Vice President, Manufacturing Operations at Nektar Therapeutics. Mr. Simms held the roles of Senior Vice President for PowderJect Pharmaceuticals and Vice President, Device Development and Manufacturing from 1998 - 2002. Mr. Simms holds a BS in Chemical Engineering from University of Missouri-Rolla and an MBA from Pepperdine University.

"We are very pleased to welcome Mike to Alexza and our Executive Team," said Thomas B. King, Alexza President and CEO. "We enter 2008 with a focus on the many late-stage development activities leading to a planned NDA submission for AZ-004 (Staccato(R) loxapine) in the next several years. Commercial scale manufacturing scale-up and global supply chain management will be important to our longer-term success. Mike brings a wealth of operations and manufacturing experience and expertise to Alexza. We look forward to his contributions to our future growth and development."

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
2. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
3. Pharmasset Appoints Michael Rogers as Chief Development Officer
4. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Genstar Names Michael Hurt to Its Strategic Advisory Board
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
9. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
10. Royea Joins Eklin Medical Systems as VP of Worldwide Sales
11. Eric K. Rowinsky Joins ADVENTRX Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., BOCARATON,Fla.,Nov.25/PRNewswire/--Formanybusi....Thenation,slargestandfastestgrowingnetworkofexper...vised bioidenticalhormones has grownthenumberof ...o36physicians -andisinprogresstoaddmorephysician-o...syear. ,, Inthepastyear ,BodyLogicMDhasopened13...
(Date:11/25/2009)...EGO,Nov.25/PRNewswire-FirstCall/--ArdeaBiosciences...,Pharm.D.,presidentandchiefexecutiveofficer,willpr...ce. , ,Presentationdetailsareasfollows:,PiperJaf...cember1,2009,Time:2:00p.m.EasternTime,Location:The...://www.corporate-ir.net/ireye/,target=,_blank,tit...
(Date:11/24/2009)... The New York investment bank KTA Capi...has agreed an AU$6.7 mil convertible note private ...private placement was arranged by KTA Capital as N... New York (PRWEB) November ...nk KTA Capital, LLC ("KTA Capital") has ...
(Date:11/24/2009)...UIS,Nov.24/PRNewswire-FirstCall/--Sigma-AldrichCor...OMXconferenceonTuesday,December1stat1:45PMGMTinLon...audiobroadcastovertheInternetavailableat http://i...ickthe"Webcast"icontoaccessthisfile. ,, About...andHighTechnologycompany.Itschemicalandbiochemical...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...and product pipeline, BOTHELL, WA and VANCOUVER, ...euticals, Inc. (NASDAQ: OGXI ), a biopharmaceutic...cialization of new therapies that address,unmet ne...udited financial,results for the third quarter and...rter 2008 Financial Results, On August 21, 2008, ...
...hua-PRNewswire/ -- Simcere Pharmaceutical,Group (N...f branded generic,pharmaceuticals and innovative a...China market, announced today its participation in... 2008. The conference will be held at,the Mandarin...cere,s chief financial officer, Frank Zhigang Zhao...
...0 InspireMD, developers of,the novel MGuard(TM) c...TM),was successfully implanted in a complex lesion...erformed by Dr. Dariusz Dudek and was broadcast,fr...fast Meeting Symposium,"A New Approach to Treating...as met with great enthusiasm and excitement. Some ...
Other Biology Technology:OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4
(Date:11/25/2009)...he course of a lifetime, the heart pumps some 250 ...rder to do this, the muscle fibers of the heart ha...ded by Dr. Wolfgang Rottbauer, vice chair of the D... Hospital (Chairman: Prof. Dr. H. A. Katus), has d...ability of the smallest muscular unit, the sarcome...
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)...ists have crystallised a protein that may help gut...protein could be used by probiotic producers to id...it to people. , "Probiotics need to interact with... and if they attach to surfaces in the gut they ar... their activity," says Dr Nathalie Juge from the I...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2New PICC Mimics Nature 50488 1New PICC Mimics Nature 50488 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 1Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 3Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 4Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 5Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 6Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 7Press Ganey Launches Community Image Solution 50480 1Press Ganey Launches Community Image Solution 50480 2Press Ganey Launches Community Image Solution 50480 3
.... , Infectious proteins known as prions have bee...E). The culprits are "incorrectly folded" proteins... bases for such prion diseases are not yet fully u...others are not? A team headed by Beat Meier (ETH Z...f Bordeaux, France) has examined two different for...
... Montreal, 13 June 2008 Researchers at the McG...sity and the University of British Columbia (UBC) ... cause an increase in serious adverse events, but ...s adverse events. , Several drugs containing com...noids, are available for medical purposes in Canad...
... discovered that a protein previously shown to hav...he formation of cysts in Autosomal Dominant Polycy...n life-threatening genetic diseases and has shown...isease in mice. , The discovery was published ...ine yesterday. , The team showed that a pro-in...
Other Biology News:Tracking prions 2Medicines derived from cannabis: a review of adverse events 2Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2
...neral description: Dish uses include large-scale c...s, hybridizations. Compatible with PBA Flexys TM ... CLS number is a new product number, created to ea...availability yet, please order under the old Sigma...
Mouse Anti-beta II Tubulin Monoclonal Antibody, Unconjugated, Clone 7B9 from Abcam
Mouse Anti-Desmoplakin I & II Monoclonal Antibody, Unconjugated, Clone DP2.15 from Meridian Life Science, Inc.
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes from BD Biosciences - Discovery Labware
Biology Products: